New Era of Lutetium-PSMA Post Approval: Perspectives, Challenges & Future

[marnieg46]

Members of HU who are following developments of treatments involving Lutetium may find the information in this video of interest.   

The link below provides access to a Webinar that was streamed on Thursday 21st July 2022 globally to 58 countries.  Some 705 participants took part coming from the various fields of specialisation that are involved with the treatment of prostate cancer including urologists, radiation oncologists and nuclear medicine technologists.   

The expert presenters included Professor Michael Hofman and Professor Declan Murphy (Australia), Professor Ken Hermann (Germany), Professor Silke Gillessen (Southern Switzerland) and Dr Louise Kostos (Australia).   

The various sessions provided information that was interesting and clearly delivered by experts renowned in their various fields.  

One area I found of particular interest was the session given by Professor Silke Gillessen who is the founder and chairperson of the Advanced Prostate Cancer Consensus Conference (APCCC).   This meeting, held every two years is attended by many hundreds of experts in PCa who vote on a number of contentious issues on the basis of - if they had everything available for their patients what would they choose.  The issues and choices offered are contentious in that they are management situations involving patients with PCa where there is no high-level evidence to support a decision.   The situations posed are interesting and would reflect situations either presently faced, or to be possibly faced in the future by many who visit this forum.    

While there is already much information available on theranostics and the use of Lutetium, if it is one area of prostate cancer treatment that you have been following, as I have, I think you'll find the time spent well rewarded.

youtu.be/9R-gAaCSoFs(Not working as expected?)

[MateoBeach]

Thank you marnieg46. Very intriguing discussion to explore, and right up my alley, as you know. I am digging into it. MB

[marnieg46 in reply to MateoBeach]

G'day Paul. I'm just sorry I didn't have the right information to ask the difference between what you had and what they are offering. I know the answer but I would have liked to have heard it from them...especially Michael.

[spw1]

Thank you for posting. I learnt a lot.

[marnieg46 in reply to spw1]

Yes me too. I especially liked all those scenarios of hard choices - the situations when there was no hard evidence to support one treatment or another and seeing what the panel of experts chose. We live in interesting times don't we!!

[Concerned-wife]

Thank you!

[marnieg46 in reply to Concerned-wife]

My pleasure. Hope you find it of interest 😊

[HopingForTheBest1]

I was one of the 700+ participants. I was able to ask, and got responses to several questions. Definitely worth listening to.

The key question for me was whether those of us who are BRCA2+ could benefit from LU177 treatment. We are typically more associated with radio-ligand sensitivity. While there is currently no robust data available, an analysis is underway using the VISION trial data. There is high interest in an ongoing trial combining LU177 with Olaparib.

[marnieg46 in reply to HopingForTheBest1]

That's interesting. Did you get an email from Michael after asking if you had any more questions like I did? I wonder what Mateo Beach (Paul) would think as he's very interested in and knowledgeable about Lutetium ? Do you know what stage the trial with Olaparib is at?

[HopingForTheBest1 in reply to marnieg46]

I understand the trial is in early stage. You might want to check clinicaltrials.gov

[marnieg46 in reply to HopingForTheBest1]

OK I will. Thanks

[Rolphs in reply to HopingForTheBest1]

I have CHEK2 mutation and my MO is debating using Olaparib or LU 177 when I become CR. Good information on VISION trial that uses both. It may have better outcomes in combination. Thanks 🙏

[d3is4me]

Thank you for this interesting video

[marnieg46 in reply to d3is4me]

Very pleased it was of interest.

[MarkEmrys]

Thanks MB. Well worth watching.

[marnieg46]

Yes it is Mark. Glad you found it of interest.